Celldex Therapeutics Announces Appointment to Board of Directors
March 01 2017 - 4:01PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the
appointment of James J. Marino, J.D., to the Company’s Board of
Directors. Mr. Marino was with the global law firm of Dechert LLP
for 28 years, where he served as Managing Partner of the Princeton,
N.J. office. His practice focused on the representation of leading
life sciences companies, both privately- and publicly-held, in a
broad range of corporate, transactional and finance matters. He
will serve as the Chairman of the Compensation Committee.
“Jim’s wealth of experience advising numerous life science
companies provides us additional perspective on the current
healthcare business environment,” said Larry Ellberger, Chairman of
the Board of Directors at Celldex Therapeutics. “His knowledge and
guidance will be important to Celldex as we advance our pipeline
through clinical development and explore multi-drug combinations to
address unmet patient needs.”
Mr. Marino currently serves on the Board of Trustees of Wake
Forest University and Wake Forest University Baptist Medical Center
and on the Board of Directors of Onconova Therapeutics, Inc. He
previously served on the Board of Directors of Pharmacopeia, Inc.
He has also worked in advisory capacities and on the boards of
multiple non-profit organizations, including Robert Wood Johnson
University Hospital. Additionally, Mr. Marino is a co-founder of
BioNJ, the trade association of biotechnology companies based in
New Jersey, which he represented from its inception. Mr. Marino
received his B.A., his M.B.A. and his J.D. from Rutgers
University.
About Celldex Therapeutics, Inc.Celldex is
developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline is
built from a proprietary portfolio of antibodies and
immunomodulators used alone and in strategic combinations to create
novel, disease-specific therapies that induce, enhance or suppress
the body's immune response. Visit www.celldex.com.
Forward Looking StatementsThis release contains
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including those related to the Company's strategic focus and the
future development and commercialization of our drug candidates and
our future goals. Forward-looking statements reflect management's
current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct or
that those goals will be achieved, and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited
to, our ability to successfully complete research and further
development and commercialization of our drug candidates; our
ability to obtain additional capital to meet our long-term
liquidity needs on acceptable terms, or at all, including the
additional capital which will be necessary to complete the clinical
trials that we have initiated or plan to initiate; our ability to
successfully integrate our and the recently acquired business of
Kolltan Pharmaceuticals, and to operate the combined businesses
efficiently; our ability to realize the anticipated benefits from
the acquisition of Kolltan; the uncertainties inherent in clinical
testing and accruing patients for clinical trials; our limited
experience in bringing programs through Phase 3 clinical trials;
our ability to manage and successfully complete multiple clinical
trials and the research and development efforts for our multiple
products at varying stages of development; the availability, cost,
delivery and quality of clinical and commercial grade materials
produced by our own manufacturing facility or supplied by contract
manufacturers, who may be our sole source of supply; the timing,
cost and uncertainty of obtaining regulatory approvals; the failure
of the market for the Company's programs to continue to develop;
our ability to protect the Company's intellectual property; the
loss of any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company's products; and other
factors listed under "Risk Factors" in our annual report on Form
10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Associate Director of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Sep 2023 to Sep 2024